- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02930967
Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors
October 11, 2016 updated by: Jinwen Sun, China Meitan General Hospital
A Safety and Efficacy Study of Chimeric Switch Receptor Modified T Cells in Patients With Recurrent or Metastatic Malignant Tumors
A Chimeric Switch Receptor, which was constructed by fusing the PD1 extracellular ligand binding domain to the CD28 intracellular costimulatory domain, was designed to target PD-L 1 positive tumors .
In this single-arm, open-label, one center, dose escalation clinical study, the main purpose is to determine the safety and efficacy of infusion of autologous Chimeric Switch Receptor modified T cells (CSR T) in adult patients with PD-L1 positive, recurrent or metastatic malignant tumors.
Study Overview
Status
Unknown
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shidong Wei, MD
- Phone Number: +86-13146634751
- Email: liqinghe9644679@163.com
Study Locations
-
-
-
Beijing, China, 100028
- Recruiting
- China Meitan General Hospital
-
Contact:
- Shidong Wei, MD
- Phone Number: +86-13146634751
- Email: liqinghe9644679@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with PD-L1 positive, recurrent or metastatic malignant tumors , including but not limited to pancreatic cancer, renal cancer, colorectal cancer, lymphoma, breast cancer and lung cancer;
- measurable tumors by RECIST1.1 standard;
- patients are 18 to 70 years old;
- life expectancy > 3months;
- KPS ≥70;
- satisfactory major organ functions: adequate heart function with LVEF≥50%; no obvious abnormities in ECG; pulse oximetry ≥ 90%; cockcroft-gault creatinine clearance≥40 ml/min; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3ULN; Bilirubin ≤2.0 mg/dl ;
- Blood: Hgb ≥ 80 g/L, ANC ≥ 1×10^9/L, PLT ≥ 50×10^9/L;
- women of reproductive potential must have a negative pregnancy test. Male and female of reproductive potential must agree to use birth control during the study and one year post study.
Exclusion Criteria:
- patients with a prior history of autoimmune disease or other diseases who need long-term use of systemic hormone drug or immunosuppressive therapy
- active infection.
- HIV positive.
- active hepatitis B virus infection or hepatitis C virus infection.
- currently enrolled in other study.
- patients, in the opinion of investigators, may not be eligible or are not able to comply with the study.
- patients with allergic disease, or are allergic to T cell products or other biological agents used in the study.
- patients whose tumors have metastasized to bone, or have clinical signs of bone metastasis, such as bone and joint pain.
- patients with brain metastasis, or have clinical signs of brain metastasis, such as loss of self-consciousness.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CSR T cells
A dose escalation clinical study aimed to assess the safety and efficacy of CSR T cells in patients with PD-L1 positive tumors. CSR T dosage ranging from: 5×10^4 /kg to 1×10^7 /kg will be tested. |
Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes.
1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as assessed by incidents of treatment related adverse events as assessed by CTCAE V4.0.
Time Frame: 2 years
|
safety of infusion of autologous CSR T cells with cyclophosphamide as lymphodepleting chemotherapy
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression-free survival
Time Frame: 6 months
|
6 months
|
|
overall survival rate
Time Frame: 2 years
|
2 years
|
|
treatment response rate of CSR T cell infusion
Time Frame: 4 weeks
|
defined as the proportion of patients who achieved complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD).
|
4 weeks
|
proliferation of CSR T cells in patients
Time Frame: 2 years
|
2 years
|
|
Persistence of CSR T cells in patients
Time Frame: 2 years
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Jinwen Sun, MD, China Meitan General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2016
Primary Completion (Anticipated)
August 1, 2018
Study Completion (Anticipated)
August 1, 2019
Study Registration Dates
First Submitted
October 10, 2016
First Submitted That Met QC Criteria
October 11, 2016
First Posted (Estimate)
October 12, 2016
Study Record Updates
Last Update Posted (Estimate)
October 12, 2016
Last Update Submitted That Met QC Criteria
October 11, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- K16-3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent PD-L1+ Malignant Tumors
-
University Medical Center GroningenActive, not recruitingLocally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 ExpressionNetherlands
-
Hoffmann-La RocheRecruitingPD-L1-selected Solid TumorsKorea, Republic of, United States, Spain, Taiwan, Turkey, Greece, Canada, Croatia, Serbia, Mexico, Cyprus, Georgia
-
Regeneron PharmaceuticalsTerminatedAdvanced PD-L1 Positive MalignanciesUnited States
-
University Hospital, MontpellierCompletedPatients Recieving Anti-PD-1 or Anti-PD-L1 ImmunotherapiesFrance
-
Baodong QinUnknown
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
Consorzio OncotechCompletedMetastatic or Locally Advanced PD-L1 Positive Urothelial CancerItaly
-
Peking University Cancer Hospital & InstituteRecruitingMelanoma | Lung Cancer | PD-L1 | PET/CTChina
-
Yonsei UniversityMerck KGaA, Darmstadt, GermanyActive, not recruitingPD-L1 Positive Mutation Tumor | EBV Positive Mutation Tumor | MSI-H Mutation Tumor | POLE/POLD1 Mutation TumorKorea, Republic of
-
Baodong QinUnknownChemotherapy Effect | Immunotherapy | Tumor Mutation Burden | PD-1/L1 InhibitorChina
Clinical Trials on autologous CSR T
-
Groupe Medical de Pneumologie, Polyclinique Saint-LaurentResMed; Slb Pharma; VitalAire; Regional Health Agency - BrittanyCompleted
-
University of PennsylvaniaCompleted
-
Hebei Senlang Biotechnology Inc., Ltd.Hebei Medical University Fourth HospitalUnknownLymphoma | LeukemiaChina
-
Imperial College LondonMedical Research Council; Imperial College Healthcare Nissen FundRecruitingRefractory AnginaUnited Kingdom
-
Catalyst OrthoScienceRecruitingOsteoarthritis Shoulder | Avascular Necrosis of the Head of Humerus | Rheumatoid Arthritis ShoulderUnited States
-
AdaptimmuneCompletedCarcinoma | Non-Small Cell Lung CancerUnited States, Spain, United Kingdom, Canada
-
Institute of Hematology and Blood Transfusion,...RecruitingNon-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory | Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaCzechia
-
Hebei Senlang Biotechnology Inc., Ltd.Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei HospitalRecruitingLymphoma | Leukemia | Multiple Myeloma of Bone (Diagnosis)China
-
The Nordic Network For Clinical Islet TransplantationActive, not recruiting